Supplementary Fig. 5: LY3214996 potently inhibits proliferation of human primary patient AML cells in a concentration-dependent manner.
From: Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia
(A, B) Proliferation studies; 3-day LY3214996 treatment (A) or 6-day treatment (B) of primary AML patient samples. (C, D) Proliferation studies; 3-day LY3214996 treatment (C) or 6-day treatment (D) of normal PBMCs versus human AML cells. (E) LY3214996 treatment of AML patient sample 14 for 3 days. (F-G) Proliferation studies; 3-day LY3214996 or AZD6244 treatment of AML patient samples 12 (F) and 13 (G). Patient and primagraft information for all samples shown in this manuscript is provided in Supplementary Tables 1 and 2.
